Fluorescence Immunoassay Test & Analyzer’s Post

🔬 Understanding Hashimoto's Disease and the Role of Magnesium 🧬    Hashimoto's disease, an autoimmune disorder, is characterized by the elevated levels of autoantibodies against essential proteins in the thyroid. This leads to chronic damage of the thyroid gland, impacting millions worldwide. Recent studies have shown that magnesium plays a crucial role in preventing thyroiditis and promoting overall well-being. 🦋✨    At #BioSystems, we are committed to improving the diagnosis of Hashimoto’s disease, and to provide a complete analytical solution. The Magnesium reagent to measure the magnesium concentration in human serum in combination with the Anti-Thyroglobulin Antibody Kit offers a complete examination of the patient’s health, ensuring appropriate and precise diagnostic. 🩺🔍    By providing reliable tools and insights, we aim to support healthcare providers in delivering the best possible care to their patients. Together, let's make strides in enhancing patient outcomes. 🌟 #HealthcareInnovation #HashimotosDisease #ThyroidHealth #Magnesium #MedicalDiagnostics #AntiThyroglobulinAntibodies #PatientCare #EarlyDetection #AutoimmunityDiseases #AutoimmuneDiagnose #HumanCentredBiotech

Thyroid Storms in its severe and treatment- resistant form can result in Decompensated Heart Failure with a high mortality rate. In our just-published literature review we narrated several cases like this. Plasma exchange and total thyroidectomy can resolve the trigger. However, the heart function barely comes back. A reminder for timely assessment and diagnosis and consideration of patients adherence to their meds. Thanks to the great team. #Heartfailure, #Grave’s, #Thyroidstorm, #PapillaryThyroidCancer

Our selected "Article of the Month": The costs analysis related to COPD, evaluated in a representative sample compared to individuals without the disease, informs that in 2019 the overall estimate of costs incurred was equal to $31.3 billion. This figure is destined to double within the next 10 years, albeit with significant national geographical differences. This evidence actualizes the enormous economic burden determined by this pathology and highlights how the complexity of the care required by these patients makes action planning necessary to rationalize resources. https://lnkd.in/grx5yTDG

🧠Prof. Tack's insightful talk on Irritable Bowel Syndrome (IBS) diagnosis is truly inspiring! 🎯Accurate diagnosis still remains an obstacle. 💡 Their is a need to overcome these challenges. This includes raising awareness about the role of gut #microbiota in IBS. The development of a dedicated diagnostic tool for IBS holds great promise for improving IBS management. 💪 Supporting patients throughout their IBS journey is also crucial. #IBS #DigestiveHealth #Diagnosis #PatientCare

Did you know: up to 75% of individuals with Irritable Bowel Syndrome (IBS) may be undiagnosed. A complex disease that remains difficult for patients to relate and understand. To help healthcare professionals, Professor Jan Tack, a gastroenterologist at Leuven University, in partnership with Pr. Jean-Marc Sabaté and Pedro Costa Moreira, has created a tool to improve diagnosis and communication with patients. In this video, Jan Tack presents the genesis of this project for the Biocodex Microbiota Institute, and discusses the connection between #IBS and #microbiota. A user friendly and scientifically valid-based approached which aims to provide better support for patients thanks to a more practical approach to the disease. And now, dear healthcare professionals, if you too are interested in IBS diagnosis tool and would like to engage more with your patients, visit our website to download it ⤵️ https://lnkd.in/e-k7eszs

📣NEW‼️: First accuracy and user-experience evaluation of new continuous glucose monitoring (CGM) system for hypoglycemia due to hyperinsulinism, published in the Journal of Diabetes Science and Technology (JDST). The authors of this important evaluation are all members of the expert staff at the Royal Manchester Children's Hospital which is a CHI Center of Excellence. The Manchester team found improvements in user experience for the latest Dexcom CGM model. Visit https://lnkd.in/eS9hvqu2 to read more. #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

A high platelet count, or thrombocytosis, can lead to blood clotting issues, causing headaches, dizziness, chest pain, and tingling in hands and feet. It's often a secondary condition linked to underlying factors such as chronic inflammation, infections, or specific medical conditions like cancer. Understanding the symptoms and causes is crucial for timely diagnosis and effective management. Read more about this condition on our blog https://zurl.co/Jjvx #rela #health #healthcare

Managing Inflammatory Bowel Disease (IBD) means more than treating symptoms—it's about reclaiming quality of life!     In this video, Dr. Kerri Novak, MD, MSc, FRCPC discusses how an intestinal ultrasound could be brought into your IBD care path!     Stay tuned for more, and read our latest article to learn all about Intestinal Ultrasound: https://lnkd.in/e8B_J8hH Pfizer #IBDAwarenessMonth #InflammatoryBowelDisease

📣 Landmark Trial Summaries, Presented by InpharmD The FINEARTS-HF trial (NCT04435626) evaluated finerenone (Kerendia™), a nonsteroidal selective MRA, in heart failure management as part of guideline-directed therapy. Finerenone significantly reduced worsening heart failure events and cardiovascular deaths compared to placebo and improved patient-reported health status (KCCQ total symptom score). However, it did not improve NYHA functional class or reduce kidney composite outcomes. Adverse events included higher rates of hyperkalemia (without fatalities) and lower rates of hypokalemia in the finerenone group. For more information, read the full blog post: https://lnkd.in/eD5ECk4M #StayInformedWithInpharmD

Check out InpharmD's blog for landmark trial summaries! We break down the most relevant information, with a strong focus on the data and clinical impact. This week we looked at the FINEARTS-HF trial, evaluating finerenone for heart failure management. While the primary outcome did show statistical significance, can we generalize this to our patient populations? What about comparisons with other MRAs? Read the full post on our blog (linked below)! #StayInformedWithInpharmD